



## (51) International Patent Classification:

*C07D 487/04* (2006.01) *A61P 35/00* (2006.01)  
*A61K 31/519* (2006.01)

## (21) International Application Number:

PCT/EP2012/055600

## (22) International Filing Date:

29 March 2012 (29.03.2012)

## (25) Filing Language:

English

## (26) Publication Language:

English

## (30) Priority Data:

11161111.7 5 April 2011 (05.04.2011) EP

(71) Applicant (for all designated States except US): **Bayer Pharma Aktiengesellschaft** [DE/DE]; Müller Strasse 178, 13353 Berlin (DE).

## (72) Inventors; and

(75) Inventors/Applicants (for US only): **PETERS, Jan, Georg** [DE/DE]; Belliniweg 6, 42719 Solingen (DE). **MILITZER, Hans-Christian** [DE/DE]; Waldweg 2, 51519 Odenthal (DE). **MÜLLER, Hartwig** [DE/DE]; Wiesenweg 10, 42553 Velbert (DE).(74) Common Representative: **Bayer Pharma Aktiengesellschaft**; Law and Patents, Patents and Licensing, Müller Strasse 178, 13353 Berlin (DE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

## Declarations under Rule 4.17:


— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

## Published:

— with international search report (Art. 21(3))

[Continued on next page]

(54) Title: SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE SALTS



. 2 HCl

(II)

(57) Abstract: The present invention relates : - to 2-amino-N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydroimidazo- [1,2-c]quinazolin-5-yl]pyrimidine-5-carboxamide dihydrochloride salt of formula (II) : or a tautomer, solvate or hydrate thereof; - to methods of preparing said dihydrochloride salt; - to said dihydrochloride salt for the treatment and/or prophylaxis of a disease; - to the use of said dihydrochloride salt for the preparation of a medicament for the treatment and/or prophylaxis of a disease, in particular of a hyper- proliferative and/or angiogenesis disorder, more particularly for the treatment or prophylaxis of a cancer, particularly lung cancer, in particular non-small cell lung carcinoma, colorectal cancer, melanoma, pancreatic cancer, hepatocyte carcinoma, pancreatic cancer, hepatocyte carcinoma or breast cancer; - to a pharmaceutical composition comprising said dihydrochloride salt; and - to a pharmaceutical combination comprising said dihydrochloride salt in combination with one or more further pharmaceutical agents.





- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*